🇺🇸 FDA

Intelligence · Patent portfolio

Sana Biotechnology Patents

Full USPTO pharma patent portfolio for Sana Biotechnology — grant dates, expiration, and drug cross-links.

Patents
136
Expiring ≤24m
2

Quick answer

Sana Biotechnology has 136 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 2 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 3

  1. US 12427199

    Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12246059

    Stable hybrid FC fusion G-CSF formulation

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12171822

    Infectious plasmodium sporozoites grown in vitro

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12156870

    Antibody drug conjugates comprising sting agonists

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12077543

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11987628

    Methods and compositions for modulating CAR-T activity

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11975082

    Production of antibacterial and regenerative dental composite using supportive phases (fillers) antibacterial and bioactive properties of which are improved

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11964024

    B7H4-targeted antibody-drug conjugates and methods of use thereof

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11964025

    Peptide-containing linkers for antibody-drug conjugates

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11965022

    Methods and compositions for modulating CAR-T activity

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11939343

    Sting agonist compounds and methods of use

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11925629

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11918627

    Dosage regimen for inhaled vasoactive intestinal polypeptide

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11883475

    Infectious Plasmodium sporozoites grown in vitro

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11813310

    Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11802157

    Methods and compositions for modulating CAR-T activity

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11786605

    Site specific antibody-drug conjugates with peptide-containing linkers

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11638760

    Pyrrolobenzodiazepine antibody conjugates

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11608275

    Method for producing zinc oxide platelets with controlled size and morphology

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11596694

    Compositions and methods for predicting response to NaPi2b-targeted therapy

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11535869

    CD8-specific antibody constructs and compositions thereof

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11518812

    Monoclonal antibodies against HER2 epitope and methods of use thereof

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11434278

    Protein-polymer-drug conjugates

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11407825

    NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11339169

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11207395

    Infectious plasmodium sporozoites grown in vitro

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11155567

    Sting agonist compounds and methods of use

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11135307

    Peptide-containing linkers for antibody-drug conjugates

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11103491

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11052123

    Method of obtaining olive oil and extracts from olives

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10947295

    Heterodimers of soluble interferon receptors and uses thereof

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10947317

    NaPi2b-targeted antibody-drug conjugates and methods of use thereof

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10912779

    Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10772971

    Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10751332

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10695296

    Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10660901

    Pyrrolobenzodiazepines and conjugates thereof

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10647720

    Pyrimido-pyridazinone compounds and methods of use thereof

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10632101

    Methods and compositions for supporting endogenous systems related to life span

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10617136

    Calcium oxide compound with high purity

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10611768

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10603386

    Protein-polymer-drug conjugates

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10590127

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10544145

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10537645

    Protein-polymer-drug conjugates

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10526294

    Pyrrolobenzodiazepines and conjugates thereof

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Sana Biotechnology have?

136 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Sana Biotechnology patents expire?

2 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.